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how perturbations in the epigenetic milieu are easily acquired 
and how they may increase the risk of CHD under certain 
circumstances. However, a thorough understanding of the 
epigenetic control of cardiogenesis implies an exciting new 
prospect namely that the environmental factors known to alter 
epigenetic mechanisms are potential targets for manipulating 
the control of heart development – either by reducing exposure 
to known cardiac teratogens, or increasing exposure to those 
factors known to reduce the incidence of CHD.
EPIDEMIOLOGY OF CHD IN THE WESTERN 
CAPE, SOUTH AFRICA: A CONUNDRUM
The Paediatric Cardiology Service of the Western Cape 
(PCSWC), based at the Red Cross War Memorial and 
Tygerberg Children’s Hospitals in Cape Town, serves the public 
health paediatric cardiology needs of the Western Cape, South 
Africa. Using the CHD incidences as given before, we could 
estimate the theoretical epidemiological demands on this 
service. During 2012, 93 394 newborn babies were recorded in 
the public health sector (Stefan Gebhardt, pers. comm). From 
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Congenital heart disease (CHD), which occurs in about 
1 per 100 live births, remains the leading life-threatening 
abnormality present at birth. It is reasonable to assume 
that most, if not all, CHD stems from errors or dis-
ruptions in the genetic control of heart development, 
and that a more thorough knowledge of these control-
ling molecular mechanisms may lead to a better under-
standing of the origins of CHD. With understanding 
comes the potential for prevention, and possibly early 
repair.
Our operational research in the Western Cape has 
identifi ed a severe epidemiological shortfall between 
the theoretical number of newborns that should present 
to us with severe CHD and those who actually do - we 
are referred only 50% of the children that (epidemi-
ologically) should receive heart surgery. Even if we 
could identify all the missing children, our services 
would be unable to contend with the consequent 
demand. This stark dilemma plays itself out in most 
resource-constrained cardiac health services. 
It is therefore of utmost importance that the origins of 
CHD that may be under environmental infl uences - “the 
epigenetic causes of CHD” - are prioritised in our quest to 
reduce heart defects. I will outline these infl uences and 
show how an understanding of them may begin to reduce 
an enormous health burden.   SAHeart 2016;13:90-96
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“There is no use trying,” said Alice, “one can’t believe impossible 
things.” 
“I dare say you haven't had much practice,” said the Queen. 
“When I was your age, I always did it for half an hour a day. Why, 
sometimes I've believed as many as six impossible things before 
breakfast.”  
    Lewis Carroll: Through the Looking Glass (1871)
It is well established that the birth incidence of congenital heart 
disease (CHD) is 8 per 1 000 live births, with some variation 
within, and between populations.(1) In developing countries, this 
incidence is higher and is set at 1%.(2) The Global Report on 
Birth Defects(3) puts CHD as the most common genetic, or 
genetic-related, birth defect accounting for more affected 
newborns than the subsequent 4 commonest defects put 
together.(4) It is also known that socio-economic profiles may 
affect this incidence, with an inverse relationship between 
socio-economic status and all birth defects, including CHD.(5) 
Approximately 60% of babies born with CHD will require an 
intervention (cardiac surgery or percutaneous catheterisation 
intervention) at some time, and half of these (3/1 000) will have 
critical (usually duct-dependent) CHD, and will need inter-
vention in the neonatal period to avoid death or severe 
morbidity.(4,6)
This article will introduce epigenetics and its role in the control 














this we can estimate (Figure 1) that the number of newborns 
requiring cardiac intervention is approximately 558 cases 
annually (of which 229 would be “critical” CHD). All paediatric 
cardiac surgery of the PCSWC (and therefore all paediatric 
cardiac surgery in the public health sector of the Western 
Cape) is performed at Red Cross Hospital only, but the total 
number of cases done rarely exceeds 300 per annum. This 
number includes staged operations (i.e. one in a series required 
by that patient, for example leading to a Fontan procedure), 
re-do operations, and patients from outside the Western Cape. 
Therefore, we estimate that a minimum of 250 new cases 
(±558 - 300) are missed in the Western Cape annually, but 
realistically, this figure is closer to 300 cases. Naturally, the 
backlog increases over time, accumulating those cases that 
survive the early critical period. 
The conundrum arises as a result of 2 major problems: firstly 
the poor recognition of children (particularly newborn babies) 
with CHD and secondly the limitation of service delivery due 
to public health sector resource constraints. This situation is 
not unique to the Western Cape, but common worldwide, 
particularly so in countries with resource-limited health care 
systems.(7) 
However, it should be recognised that effective ascertainment 
and efficient service delivery can reduce the prevalence of 
CHD, but not its incidence. It may therefore be important to 
start focusing on alternative strategies to reduce the incidence 
of CHD. Is this at all possible?
THE AETIOLOGICAL LANDSCAPE OF 
CONGENITAL HEART DISEASE
Many associations between well-defined genetic conditions and 
heart defects are known.(8) The most common (Figure 2) are 
those of chromosomal defects linked to a specific set of heart 
defects. Some examples include Down syndrome with endo-
cardial cushion defects, the 22q11.2 deletion syndrome with 
conotruncal lesions, Turner syndrome with coarctation of the 
aorta, and Williams syndrome with pulmonary and aortic root 
stenosis. In addition, there are many conditions caused by single 
gene mutations known to be associated with a limited suite of 
heart defects, such as Marfan syndrome (fibrillin gene mutation) 
with mitral valve and aortic root dilatation, Alagille syndrome 
(Jagged-1 gene mutation) with tetralogy of Fallot, and Noonan 
syndrome (PTPN11 gene mutation) with pulmonary stenosis 
and hypertrophic cardiomyopathy. While these are frequent 
associations, the “usual or characteristic” lesions are not 
invariably present. Indeed, only 49% of children with Down 
syndrome will have associated CHD(9) and a child with, for 
example, Alagille syndrome will not invariably have a right 
ventricular outflow tract lesion. Furthermore, there are many 
FIGURE 1:  The epidemiological demand on the Paediatric Cardiology Service of the Western Cape for congenital heart surgery as 
exemplifi ed by recorded birth data from 2012 (birth data courtesy of Stefan Gebhardt, Tygerberg Hospital). (Figure by author.) 
The epidemiology of CHD in the Western Cape with an estimate of the case load
93 394 babies born in 2012
Stefan Gebhardt, Tygerberg Hospital 
(pers. comm.)
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per year in 
the Western Cape!     
novel associations between children with, as yet, undefined 
dysmorphism with extracardiac comorbidities that may be 
associated with any of a large number of heart lesions. 
Added together, these associations of CHD, with known 
genetic syndromes and other lesser or unknown dysmorphic 
conditions, account for only 20% of children born with 
CHD.(8,10) In the majority, the heart defect is solitary (or 
sporadic), thus the only congenital defect in a non-syndromic 
child with no known family history. Until recently these heart 
defects have posed an enigma: what is the exact cause of 
the isolated heart lesion when a search for a causative gene 
often proves to be futile? The lesion may be a common one 
(e.g. VSD, tetralogy of Fallot or ASD) yet it is usually fruitless to 
search for a mutated gene, and an extended family tree or 
cascade screening may be pointless. In addition, the recurrence 
risk for the children of survivors of isolated CHD surgery is 
unpredictable, and is empirically set at 3 - 5% (depending on 
the lesion), but this prediction cannot be made with any 
certainty as in the case of dominant or recessive genetic trans-
mission patterns. 
THE GENETIC CAUSES OF CHD
Despite this uncertainty, Helen Taussig’s contention(11) remains 
highly probable that nearly all CHD stems from errors during 
the genetic control of embryonic heart development, if not 
by direct genetic alteration, then by changes to the control-
ling elements of normal genes that result in an altered 
phenotype.(4,12) Cardiac embryogenesis is an extremely complex 
process, but recently rapid and astounding developments have 
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Genetics of heart development
FIGURE 2:  The aetiological landscape of congenital heart disease showing the relationships of the various forms of genetic aetiologies of 
congenital heart disease. (Figure by author.)
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occurred in gene discovery, in the detailed descriptions of the 
embryology of model organisms, in the elucidation of the 
causative genetic mechanisms in many known cardiogenetic 
syndromes, and following the full sequencing of the (protein-
expressing) human genome in 2003. This progress has allowed 
huge strides to be made in elucidating the causes of many 
CHDs. However, this success has rapidly exposed and empha-
sised the unknown and, until very recently, the cause(s) of 
isolated CHD has remained obscure. 
It is only with the very recent onset of studies into human 
epigenetics that it has become possible to speculate, with more 
evidence, as to the causes of the common non-syndromic and 
isolated heart lesions.(8) The crux lies in the realisation that it 
may be the control of heart development that is perturbed, 
rather than the structural, protein-coding genes per se. 
WHAT IS EPIGENETICS AND WHAT ROLE 
DOES IT PLAY IN HEART DEVELOPMENT? 
A detailed description of the rapidly burgeoning field of 
epigenetics and its fundamental role in embryogenesis is beyond 
the scope of this article, but a brief outline of its importance in 
cardiogenesis follows.
In 2011 Gottesfeld(13) wrote: “Each cell type in an organism 
expresses a distinct set of genes…but all cells have the same DNA 
or genes. A fertilised egg, or zygote, changes into the numerous cell 
types of an organism…by the programmed expression or repression 
of classes of genes.” Epigenetics is therefore the combination of 
all the mechanisms that control the expression of the genes 
involved in the normal development of all tissues and organs, be 
they DNA sequences that code for structural proteins, or those 
that code for regulatory proteins such as transcription factors. 
Only the coding DNA sequences (or roughly 21 000 genes) of 
these proteins were elucidated by the Human Genome Project 
in 2001(14,15) and they form only approximately 3% of the entire 
DNA complement in each cell.(16) Much of the remaining DNA 
contains regulatory elements, or conserved non-coding ele-
ments,(17) that control the expression of the coding DNA at the 
exact time and in precisely the correct sequence and amounts. 
These are the “factors and processes around DNA that regulate 
genome activity independent of the DNA sequence and that 
are mitotically and meiotically stable”, as Skinner(18) defined 
epigenetics in 2011. 
Genes are inheritable, and as building blocks they are passed on 
unchanged to progeny, unless they are mutated during game-
togenesis, thereby potentially causing a genetic problem which 
may, or may not, cause congenital defects. But in addition, the 
epigenetic, controlling factors are also inheritable in a stable way 
to continue their process of expression control in the offspring. 
Thus, another and more recent definition(19) of epi-genetics is 
“the changes in the regulation of gene expression that can be 
passed on to a cell’s progeny but are not due to changes to the 
nucleotide sequence of the gene.” 
Language is a useful analogy to help understand epigenetic 
mechanisms. Think of a language as a system which is built up 
of only 26 letters of the alphabet which make words (as genes). 
These words themselves, and their uses, are governed by the 
fundamental rules of spelling and grammar (the epigenetic 
factors) that remain unseen in written and spoken language. 
However, the epigenetic factors themselves are not immune to 
damage and alteration(20) but are changeable, being sensitive 
and alterable by many environmental factors. The transcription 
factors may be mutated, thereby altering their controlling 
effects, or direct environmental damage to epigenetic factors 
may occur. These altered influences or damaged control 
regulation of gene expression may either cause cardiac lesions 
by maldevelopment (e.g. a VSD) or by arrested normal 
development of the heart, the so-called atavisms or heart 
development stopped at a phase that would be normal for an 
evolutionary predecessor,(21) e.g. the 3-chambered heart of a 
frog, or the septal defects of a reptile.(22) Furthermore, such 
lesions have significant “downstream” haemodynamic effects 
with serious anatomical sequelae, such as hypoplastic pul-
monary arteries, or severe pulmonary hypertension.
In our language analogy, all English language speakers use the 
same alphabet, but environmental influences create major 
differences between Oxford English and the English spoken in 
Australia, America, or Jamaica. Furthermore, the same alphabet 
is dramatically altered by the environment to form the words of 
different languages, such as French, German or Danish. But only 
the native speakers will realise (and sometimes understand) the 
mistakes when those who do not obey the spelling or grammar 
rules damage their language. Similarly, we should search for the 
epigenetic factors that incorrectly control the expression of 
structural and controlling genes and thereby cause cardiac 
maldevelopment or atavisms. 
Skinner(18) commented that: “The paradigm that genetics is the 
primary factor to regulate developmental biology is limited and 
ignores the plasticity to respond rapidly to environment, nor does it 
explain abnormal development and disease etiology in the absence 
of genetic alterations” (my emphasis). These insights, and others 
akin to it, begin to give concrete meaning to Taussig’s(11) 
remarkable foresight that understanding the molecular mecha-
nisms of heart development may allow us to understand CHD. 
The crux of these comments is that with the understanding of 
aetiology and pathogenesis, the possibility arises to (a) recognise 
and avoid pathogenic environmental triggers, or (b) manipulate 
epigenetic controls to achieve reductions in errors of cardiac 
maldevelopment. 
IMPORTANT ENVIRONMENTAL FACTORS IN 
CHD PATHOGENESIS
The importance of environmental influences on the aetiology 
of CHD has long been recognised. It formed one of the central 
investigations of one of the most fundamental and influential 
studies into the epidemiology of CHD, the Baltimore-
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Washington Infant Study (BWIS).(23) Their fundamental hypo-
thesis included an assessment of the contributions of environ-
mental exposure, exposure route and genetic susceptibility to 
congenital abnormalities at birth. When one considers that 
this work was done before the era of genomics in the current 
millennium, their goals seemed very ambitious, but it never-
theless made many valuable contributions to this field.(24) 
Since the BWIS, many extensive studies of nongenetic (environ-
mental) factors influencing the incidence of CHD have been 
performed.(25) Patel and Burns(26) summarised these in a meta-
analysis in 2013. Figure 3 summarises the most significant 
environmental factors from their study in terms of the most 
significant odds ratios for the risk of CHD. Note that most are 
common environmental factors that are amenable to targeted 
strategies for risk reduction. Trichloroethylene had an OR of as 
high as 14.5 for inducing cardiac lesions, and this is one of the 
reasons its use has been abandoned. 
However, despite compiling these large studies of associations 
and the high relative risks of some known environmental risk 
factors for CHD, few significant advances have been made in 
understanding their precise aetiological mechanisms. Under-
standing these well will better substantiate motivations for the 
implementation of strategies to reduce exposure to known 
pathogenic risk factors. Epigenetics provides the causal link to 
the environmental influence of genetic regulation(27) – this helps 
to deconstruct the nature, nurture contradistinction and begins 
to remove its facile dichotomy. 
ALCOHOL EXPOSURE: EVIDENCE FOR 
EPIGENETIC DAMAGE
Evidence from molecular biology corroborates these epi-
demiological associations. An environmental risk factor that has 
been well studied is alcohol; periconceptional exposure to 
ethanol has become one of the best studied teratogens in fetal 
alcohol spectrum disorders.(28) 
In mouse models of fetal alcohol syndrome disorders, alcohol 
exposure induced aberrant changes in DNA methylation pat-
terns with associated changes in gene expression.(29) Evidence 
has also been found to suggest that chronic alcohol use 
demethylates normally hypermethylated regions in sperm 
DNA.(30) This illustrates how environmental changes to the 
epigenome may become transgenerational. Such studies have 
highlighted the importance of paternal teratogen exposure to 
increasing risk of cardiac maldevelopment of offspring. 
THE PROMISE OF FOLATE: EVIDENCE FOR 
EPIGENETIC PROTECTION
In 2009, Ionescu-Ittu, et al.(31) published a landmark epi-
demiological study of the incidence of severe CHD in Quebec, 
Canada, before and after the implementation of mandatory 
folic acid fortification of grain products in Canada in 1998. The 
time trend analysis revealed a significant year-on-year reduc-
tion in the incidence of severe CHD (6.2% per year over 
5 years) after 1998. This powerfully associated an increase in 
an environmental factor (folate) with reduction in the risk of 
newborn CHD.
Subsequent studies, such as those in the Netherlands by Van 
Beynum, et al. in 2010,(32) have substantiated these findings 
epidemiologically. A meta-analysis of 18 studies, published in 
2015,(33) has provided evidence that maternal folate supple-
mentation is associated with a decreased risk of CHDs (Relative 
risk: 0.72, 95% CI: 0.63 - 0.82). They describe this as providing 
“robust” evidence of the positive effect of maternal folate 
fortification and reduced risk of CHD.
Fortification of staple foods with folate was introduced in South 
Africa in October 2003, resulting in a 30.5% reduction in the 
incidence of neural tube defects by 2005.(34) Unfortunately, to 
date, no studies of the incidence of CHD has been under-
taken in South Africa, and it is not known whether the folate 
fortification in 2003 has subsequently had an impact on the 
incidence of CHD. 
Work by several groups has shown associations between gene 
variants in the folate metabolic pathway and an increased risk 
for CHD, but specifically associated with the group of cono-
truncal defects.(35) On the other hand, a large and comprehensive 
assessment(36) of the relationship between left-sided cardiac 
defects and folate-related genes has shown little evidence that 
the origins of left-sided heart defects, such as hypoplastic left 
FIGURE 3: The ranges of odds ratios of some of the most 
signifi cant non-genetic risk factors for congenital heart disease. 
The protective effect of folate is shown (in red).  Figure by 
author from data summarised from Patel and Burns.(26)
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heart syndrome, coarctation of the aorta, bicuspid aortic valve, 
aortic valve stenosis or isolated mitral valve anomalies, are 
folate related.
ENVIRONMENT-EPIGENETIC INTERACTION
It has become clear that chemical changes in, and around, cells 
may affect the epigenetic control of genes by triggering altera-
tions in the way genes are switched on or off.(37) Such chemical 
influences may even include diet, stress levels and prenatal 
nutrition or care.(38) Some of the best-studied alterations are 
those that activate epigenetic marks that modify the production 
of proteins, such as histones.(39) In the USA, the Environmental 
Protection Agency has identified known teratogenic substances 
of which the most harmful are lead, mercury, cocaine, alcohol, 
tobacco, heroin, iodized radiation and dioxin.(40) Fetal develop-
ment is altered by these common teratogens due to the 
permanent epigenetic changes in the structure and control of 
genes.
As far back as 1987, the paleontologist Stephen Jay Gould(41) 
wrote that “we must seek to understand the emergent and 
irreducible properties arising from an inextricable interpenetration 
of genes and environment.” While, strictly speaking, he was not 
writing about congenital defects, he was arguing for a reas-
sessment of the ingrained notion of genetics and environment 
being completely separate influences on social biology. Margaret 
Lock, a Canadian anthropologist, takes this argument further, 
but within the medical realm, as she argues for the abolishment 
of the false assumption of a rigid distinction between nature 
and nurture. She writes(42) cogently that “epigenetic findings 
strongly suggest that history, politics, social environments, racism, 
and discrimination must be given consideration equal to or greater 
than that of the immediate family circumstances, thus posing 
challenging questions for the location of responsibility for ill 
health” (my emphasis). She goes on to point out that epigenetics 
introduces the notion that “your behaviour” may generate 
malformations in your children and grandchildren!
To this we may add our responsibility to apply the increasing 
evidence from these new epigenetic insights, firstly to reduce 
periconceptual exposure to high-risk epigenetic factors, as 
mentioned above, and secondly to better advocate proven 
protective factors, such as periconceptual folate supplementa-
tion, to minimise the risk further. It should be our behaviour to 
inform and guide those at highest risk of inducing epigenetic 
causes of malformations to their progeny. 
CONCLUSION
We must realise that termination of pregnancy, medication, 
interventional catheterisation, and cardiac surgery are not our 
only methods to combat children’s heart disease. Epidemiology 
has elucidated mechanisms whereby epidemiological suspicions 
may, in time, be substantiated as aetiological certainty, opening 
the potential for well-informed, evidence-based prevention (or 
possibly early correction) of congenital heart disease. However, 
wider perspectives from epigenetics indicate that we should 
also focus on ameliorating the social triggers and precedents of 
cardiac maldevelopment. 
Epigenetics has now clearly been shown to play an important 
role in the control of the expression of developmental genes. It 
is also known that perturbations in the epigenetic milieu are 
easily acquired from many environmental and social factors that 
may increase the risk of CHD. The precise mechanisms of 
action of many, perhaps most, of these environmental influences 
on the control of developmental genes remain to be elucidated. 
Understanding these epigenetic influences on cardiac embryo-
genesis may suggest targets for manipulating the control of 
heart development. With clear insight into its aetiology, we may 
begin to dream of the ways to reduce the incidence of CHD.(8) 
But here is an exciting new prospect that we, as clinicians, 
should advocate: to encourage the further elucidation of those 
factors in the social environments of our patient populations 
that may be deleterious to heart development, and encourage 
the introduction of proven factors that reduce the incidence of 
CHD. In a resource-limited society, social upliftment may be 
our strongest epigenomic medicine!
“DNA, we thought, was an iron-clad code that we and our children 
and their children had to live by. Now we can imagine a world in 
which we tinker with DNA, bend it to our will.”(38)
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